leadf
logo-loader
viewErgomed PLC

Ergomed to help run second trial in Italy targeting possible coronavirus treatments

The programme is being conducted at the Humanitas Research Hospitals in Bergamo and Milan

Virus
The drug is currently in late-stage trials for rheumatoid arthritis

Ergomed PLC (LON:ERGO) is to work on a second clinical trial in Italy looking at ways to tackle people severely ill with coronavirus (COVID-19).

The trial will target the GM-CSF cytokine using a drug currently in late-stage trials for rheumatoid arthritis developed by Oxford-based Izana Bioscience.

Namilumab is a monoclonal antibody therapy targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory immune response or cytokine that plays a central role in a broad range of immune-mediated diseases.

Ergomed said the cytokine has been found in higher levels of COVID-19 intensive care patients and early treatment to suppress it might help halt the progress of coronavirus related illness.

In a statement, Someit Sidhu, chief executive of Izana said: “Evidence suggests that anti GM-CSF therapy has the potential to change the way patients' immune systems respond to the virus, and therefore to reduce dangerous inflammation and support recovery."

The programme is being conducted at the Humanitas Research Hospitals in Bergamo and Milan.

Ergomed is already involved in a study at the Papa Giovanni XXIII Hospital in Bergamo into siltuximab, an approved rheumatoid arthritis option that targets the IL-6 cytokine, as a treatment for COVID-19 patients who develop serious respiratory complications.

Quick facts: Ergomed PLC

Price: 930 GBX

AIM:ERGO
Market: AIM
Market Cap: £453.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE fights back after bruising start to week

The FTSE is fighting back after enduring the worst sell-off since June on Monday.  UK Prime Minister Boris Johnson will address the nation today about more possible lockdowns after announcing pubs, bars, restaurants and other hospitality venues in England must close by...

on 22/9/20

2 min read